Who is sponsoring NCT02467075?

NCT02467075 is sponsored by University of Michigan.

What condition does NCT02467075 study?

NCT02467075 studies Acute Kidney Injury.

What drugs are being tested in NCT02467075?

Interventions: Iopamidol 300 (Contrast), Placebo (Normal Saline).

What is the status of NCT02467075?

NCT02467075 is currently TERMINATED.

Last reviewed 2017-05-23 · How we verify

Phase IV Randomized Double-Blinded Placebo-Controlled Noninferiority Study of the Effect of Intravenous Low-Osmolality Iodinated Contrast Material On Renal Function in Postoperative Adults With Stage IIIb or Stage IV Chronic Kidney Disease

NCT02467075 Phase 4 TERMINATED Results posted

This double-blinded placebo-controlled study will examine the incidence and significance of contrast-induced acute kidney injury following IV iodine-based contrast material administration in subjects with stage IIIB or stage IV chronic kidney disease. Subjects will be scheduled for clinically indicated CT of the abdomen and/or pelvis to evaluate for suspected intra-abdominal infection. Subjects will be randomized to receive either weight-based low-osmolality iodinated contrast material or saline. The primary outcome measure will be the incidence of stage II AKI by AKIN (Acute Kidney Injury Network) criteria.

Details

Lead sponsor	University of Michigan
Phase	Phase 4
Status	TERMINATED
Enrolment	1
Start date	2015-07
Completion	2015-09

Conditions

Acute Kidney Injury

Interventions

Iopamidol 300 (Contrast)
Placebo (Normal Saline)

Primary outcomes

Participants With Stage II AKI (Acute Kidney Injury) — 48 hours
Participants who had Stage II AKI. This is measured by comparing an initial blood creatinine level with the level at 48 hours. Creatine is a chemical waste product that passes through the kidneys. Creatinine levels reflect how well the kidneys are working.

Countries

United States